Form 4 Filing for Black Diamond Therapeutics, Inc.

Garry E. Menzel, a director at Black Diamond Therapeutics, Inc., acquired 40,000 stock options on June 26, 2026. These options, with a strike price of $1.71, are for the company's Common Stock. The options vest in full on the earlier of June 26, 2027, or the next annual meeting of stockholders, contingent upon Menzel's continued service. The options expire on June 25, 2036. The filing indicates a direct ownership nature for these derivative securities. The transaction was reported on Form 4, filed on June 29, 2026.